Bmi-1: At the crossroads of physiological and pathological biology

Genes and Diseases

Volumn 2, Issue 3, 2015, Pages 225-239

  Bhattacharya, Resham ^a   Banerjee Mustafi, Soumyajit ^a   Street, Mark ^a   Dey, Anindya ^a   Dwivedi, Shailendra Kumar Dhar ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Aging; Bmi 1; Cancer; Post translational modification; Stem cell

Indexed keywords

BMI1 PROTEIN; MICRORNA; POLYCOMB GROUP PROTEIN; TRANSCRIPTION FACTOR;

BREAST CANCER; CANCER PROGNOSIS; CANCER STEM CELL; CARCINOGENESIS; CELL AGING; CELL CYCLE; CELL RENEWAL; CHROMATIN STRUCTURE; COLORECTAL CANCER; DNA DAMAGE; DRUG TARGETING; GENE SILENCING; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; INTESTINE CANCER; LEUKEMIA; LIVER CELL CARCINOMA; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MEDULLOBLASTOMA; MOLECULAR BIOLOGY; NASOPHARYNX CARCINOMA; NONHUMAN; OVARY CANCER; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; SKIN CANCER; STEM CELL; TONGUE CANCER; TRANSCRIPTION REGULATION;

EID: 84978096840     PISSN: None     EISSN: 23523042     Source Type: Journal    
DOI: 10.1016/j.gendis.2015.04.001     Document Type: Review

References (153)

1. van Lohuizen M., Verbeek S., Scheijen B., Wientjens E., van der Gulden H., Berns A. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 1991, 65:737-752.
2. Alkema M.J., Wiegant J., Raap A.K., Berns A., van Lohuizen M. Characterization and chromosomal localization of the human proto-oncogene BMI-1. Hum Mol Gene 1993, 2:1597-1603.
3. Raaphorst F.M. Deregulated expression of Polycomb-group oncogenes in human malignant lymphomas and epithelial tumors. Hum Mol Genet 2005, 14(Spec No 1):R93-R100.
4. van der Lugt N.M., Domen J., Linders K., et al. Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes Dev 1994, 8:757-769.
5. Li Z., Cao R., Wang M., Myers M.P., Zhang Y., Xu R.M. Structure of a Bmi-1-Ring1B polycomb group ubiquitin ligase complex. J Biol Chem 2006, 281:20643-20649.
6. Cao L., Bombard J., Cintron K., Sheedy J., Weetall M.L., Davis T.W. BMI1 as a novel target for drug discovery in cancer. J Cell Biochem 2011, 112:2729-2741.
7. Ginjala V., Nacerddine K., Kulkarni A., et al. BMI1 is recruited to DNA breaks and contributes to DNA damage-induced H2A ubiquitination and repair. Mol Cell Biol 2011, 31:1972-1982.
8. Itahana K., Zou Y., Itahana Y., et al. Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1. Mol Cell Biol 2003, 23:389-401.
9. Brennan R.G., Matthews B.W. The helix-turn-helix DNA binding motif. J Biol Chem 1989, 264:1903-1906.
10. Rechsteiner M., Rogers S.W. PEST sequences and regulation by proteolysis. Trends Biochem Sci 1996, 21:267-271.
11. Yadav A.K., Sahasrabuddhe A.A., Dimri M., Bommi P.V., Sainger R., Dimri G.P. Deletion analysis of BMI1 oncoprotein identifies its negative regulatory domain. Mol Cancer 2010, 9:158.
12. Cohen K.J., Hanna J.S., Prescott J.E., Dang C.V. Transformation by the Bmi-1 oncoprotein correlates with its subnuclear localization but not its transcriptional suppression activity. Mol Cell Biol 1996, 16:5527-5535.
13. Ringrose L., Paro R. Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins. Annu Rev Genet 2004, 38:413-443.
14. Sauvageau M., Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 2010, 7:299-313.
15. Di Croce L., Helin K. Transcriptional regulation by Polycomb group proteins. Nat Struct Mol Biol 2013, 20:1147-1155.
16. Davidovich C., Goodrich K.J., Gooding A.R., Cech T.R. A dimeric state for PRC2. Nucleic Acids Res 2014, 42:9236-9248.
17. Cao Q., Wang X., Zhao M., et al. The central role of EED in the orchestration of polycomb group complexes. Nat Commun 2014, 5:3127.
18. Park I.K., Qian D., Kiel M., et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 2003, 423:302-305.
19. Liu J., Cao L., Chen J., et al. Bmi1 regulates mitochondrial function and the DNA damage response pathway. Nature 2009, 459:387-392.
20. Yan K.S., Chia L.A., Li X., et al. The intestinal stem cell markers Bmi1 and Lgr5 identify two functionally distinct populations. Proc Natl Acad Sci U S A 2012, 109:466-471.
21. Huang R., Cheung N.K., Vider J., et al. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas. FASEB J 2011, 25:4138-4149.
22. Martin A., Cano A. Tumorigenesis: twist1 links EMT to self-renewal. Nat Cell Biol 2010, 12:924-925.
23. Wang Z., Zheng Y., Park H.J., et al. Targeting FoxM1 effectively retards p53-null lymphoma and sarcoma. Mol Cancer Ther 2013, 12:759-767.
24. Nowak K., Kerl K., Fehr D., et al. BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas. Nucleic Acids Res 2006, 34:1745-1754.
25. Yang J., Chai L., Liu F., et al. Bmi-1 is a target gene for SALL4 in hematopoietic and leukemic cells. Proc Natl Acad Sci U S A 2007, 104:10494-10499.
26. Yu T., Chen X., Zhang W., et al. Regulation of the potential marker for intestinal cells, Bmi1, by beta-catenin and the zinc finger protein KLF4: implications for colon cancer. J Biol Chem 2012, 287:3760-3768.
27. Guo W.J., Zeng M.S., Yadav A., et al. Mel-18 acts as a tumor suppressor by repressing Bmi-1 expression and down-regulating Akt activity in breast cancer cells. Cancer Res 2007, 67:5083-5089.
28. Guo W.J., Datta S., Band V., Dimri G.P. Mel-18, a polycomb group protein, regulates cell proliferation and senescence via transcriptional repression of Bmi-1 and c-Myc oncoproteins. Mol Biol Cell 2007, 18:536-546.
29. Bommi P.V., Dimri M., Sahasrabuddhe A.A., Khandekar J., Dimri G.P. The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors. Cell Cycle 2010, 9:2663-2673.
30. Wang H.B., Liu G.H., Zhang H., et al. Sp1 and c-Myc regulate transcription of BMI1 in nasopharyngeal carcinoma. FEBS J 2013, 280:2929-2944.
31. Bhattacharya R., Nicoloso M., Arvizo R., et al. MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res 2009, 69:9090-9095.
32. Sugihara H., Ishimoto T., Watanabe M., et al. Identification of miR-30e* regulation of Bmi1 expression mediated by tumor-associated macrophages in gastrointestinal cancer. PloS One 2013, 8:e81839.
33. Dang Z., Xu W.H., Lu P., et al. MicroRNA-135a inhibits cell proliferation by targeting Bmi1 in pancreatic ductal adenocarcinoma. Int J Biol Sci 2014, 10:733-745.
34. Dimri M., Carroll J.D., Cho J.H., Dimri G.P. microRNA-141 regulates BMI1 expression and induces senescence in human diploid fibroblasts. Cell Cycle 2013, 12:3537-3546.
35. Chang X., Sun Y., Han S., Zhu W., Zhang H., Lian S. MiR-203 inhibits melanoma invasive and proliferative abilities by targeting the polycomb group gene BMI1. Biochem Biophys Res Commun 2015, 456:361-366.
36. Qi X., Li J., Zhou C., Lv C., Tian M. MicroRNA-320a inhibits cell proliferation, migration and invasion by targeting BMI-1 in nasopharyngeal carcinoma. FEBS Lett 2014, 588:3732-3738.
37. Sustackova G., Kozubek S., Stixova L., et al. Acetylation-dependent nuclear arrangement and recruitment of BMI1 protein to UV-damaged chromatin. J Cell Physiol 2012, 227:1838-1850.
38. Ismail I.H., Gagne J.P., Caron M.C., et al. CBX4-mediated SUMO modification regulates BMI1 recruitment at sites of DNA damage. Nucleic Acids Res 2012, 40:5497-5510.
39. Voncken J.W., Niessen H., Neufeld B., et al. MAPKAP kinase 3pK phosphorylates and regulates chromatin association of the polycomb group protein Bmi1. J Biol Chem 2005, 280:5178-5187.
40. Nacerddine K., Beaudry J.B., Ginjala V., et al. Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer. J Clin Invest 2012, 122:1920-1932.
41. Liu Y., Liu F., Yu H., et al. Akt phosphorylates the transcriptional repressor bmi1 to block its effects on the tumor-suppressing ink4a-arf locus. Sci Signal 2012, 5. ra77.
42. Sahasrabuddhe A.A., Dimri M., Bommi P.V., Dimri G.P. BetaTrCP regulates BMI1 protein turnover via ubiquitination and degradation. Cell Cycle 2011, 10:1322-1330.
43. Kennison J.A. The Polycomb and trithorax group proteins of Drosophila: trans-regulators of homeotic gene function. Annu Rev Genet 1995, 29:289-303.
44. Lund A.H., van Lohuizen M. Epigenetics and cancer. Genes Dev 2004, 18:2315-2335.
45. Valk-Lingbeek M.E., Bruggeman S.W., van Lohuizen M. Stem cells and cancer; the polycomb connection. Cell 2004, 118:409-418.
46. Akasaka T., Kanno M., Balling R., Mieza M.A., Taniguchi M., Koseki H. A role for mel-18, a Polycomb group-related vertebrate gene, during theanteroposterior specification of the axial skeleton. Development 1996, 122:1513-1522.
47. Core N., Bel S., Gaunt S.J., et al. Altered cellular proliferation and mesoderm patterning in Polycomb-M33-deficient mice. Development 1997, 124:721-729.
48. Sparmann A., van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 2006, 6:846-856.
49. del Mar Lorente M., Marcos-Gutierrez C., Perez C., et al. Loss- and gain-of-function mutations show a polycomb group function for Ring1A in mice. Development 2000, 127:5093-5100.
50. van der Lugt N.M., Alkema M., Berns A., Deschamps J. The Polycomb-group homolog Bmi-1 is a regulator of murine Hox gene expression. Mech Dev 1996, 58:153-164.
51. Jacobs J.J., Kieboom K., Marino S., DePinho R.A., van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999, 397:164-168.
52. Sherr C.J. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001, 2:731-737.
53. Sharpless N.E. Ink4a/Arf links senescence and aging. Exp Gerontol 2004, 39:1751-1759.
54. Molofsky A.V., Pardal R., Iwashita T., Park I.K., Clarke M.F., Morrison S.J. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 2003, 425:962-967.
55. O'Carroll D., Erhardt S., Pagani M., Barton S.C., Surani M.A., Jenuwein T. The polycomb-group gene Ezh2 is required for early mouse development. Mol Cell Biol 2001, 21:4330-4336.
56. Puschendorf M., Terranova R., Boutsma E., et al. PRC1 and Suv39h specify parental asymmetry at constitutive heterochromatin in early mouse embryos. Nat Genet 2008, 40:411-420.
57. Dupressoir A., Lavialle C., Heidmann T. From ancestral infectious retroviruses to bona fide cellular genes: role of the captured syncytins in placentation. Placenta 2012, 33:663-671.
58. Tanaka S., Kunath T., Hadjantonakis A.K., Nagy A., Rossant J. Promotion of trophoblast stem cell proliferation by FGF4. Science 1998, 282:2072-2075.
59. Medema R.H., Macurek L. Checkpoint control and cancer. Oncogene 2012, 31:2601-2613.
60. Park I.K., Morrison S.J., Clarke M.F. Bmi1, stem cells, and senescence regulation. J Clin Investi 2004, 113:175-179.
61. Dimri G.P., Martinez J.L., Jacobs J.J., et al. The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res 2002, 62:4736-4745.
62. Calao M., Sekyere E.O., Cui H.J., et al. Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation. Oncogene 2013, 32:3616-3626.
63. Su W.J., Fang J.S., Cheng F., Liu C., Zhou F., Zhang J. RNF2/Ring1b negatively regulates p53 expression in selective cancer cell types to promote tumor development. Proc Natl Acad Sci U S A 2013, 110:1720-1725.
64. Molofsky A.V., He S., Bydon M., Morrison S.J., Pardal R. Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. Genes Dev 2005, 19:1432-1437.
65. Hahn W.C., Counter C.M., Lundberg A.S., Beijersbergen R.L., Brooks M.W., Weinberg R.A. Creation of human tumour cells with defined genetic elements. Nature 1999, 400:464-468.
66. Ventura A., Kirsch D.G., McLaughlin M.E., et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007, 445:661-665.
67. Douglas D., Hsu J.H., Hung L., et al. BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression. Cancer Res 2008, 68:6507-6515.
68. Datta S., Hoenerhoff M.J., Bommi P., et al. Bmi-1 cooperates with H-Ras to transform human mammary epithelial cells via dysregulation of multiple growth-regulatory pathways. Cancer Res 2007, 67:10286-10295.
69. Bruggeman S.W., Hulsman D., Tanger E., et al. Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell 2007, 12:328-341.
70. Sperka T., Wang J., Rudolph K.L. DNA damage checkpoints in stem cells, ageing and cancer. Nat Rev Mol Cell Biol 2012, 13:579-590.
71. Kim W.Y., Sharpless N.E. The regulation of INK4/ARF in cancer and aging. Cell 2006, 127:265-275.
72. Xu C.R., Lee S., Ho C., et al. Bmi1 functions as an oncogene independent of Ink4A/Arf repression in hepatic carcinogenesis. Mol Cancer Res 2009, 7:1937-1945.
73. Piunti A., Rossi A., Cerutti A., et al. Polycomb proteins control proliferation and transformation independently of cell cycle checkpoints by regulating DNA replication. Nat Commun 2014, 5:3649.
74. Lessard J., Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 2003, 423:255-260.
75. Wiederschain D., Chen L., Johnson B., et al. Contribution of polycomb homologues Bmi-1 and Mel-18 to medulloblastoma pathogenesis. Mol Cell Biol 2007, 27:4968-4979.
76. Wang E., Bhattacharyya S., Szabolcs A., et al. Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer. PloS One 2011, 6:e17918.
77. Facchino S., Abdouh M., Chatoo W., Bernier G. BMI1 confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery. J Neurosci 2010, 30:10096-10111.
78. Ismail I.H., Andrin C., McDonald D., Hendzel M.J. BMI1-mediated histone ubiquitylation promotes DNA double-strand break repair. J Cell Biol 2010, 191:45-60.
79. Bentley M.L., Corn J.E., Dong K.C., Phung Q., Cheung T.K., Cochran A.G. Recognition of UbcH5c and the nucleosome by the Bmi1/Ring1b ubiquitin ligase complex. EMBO J 2011, 30:3285-3297.
80. Bergink S., Salomons F.A., Hoogstraten D., et al. DNA damage triggers nucleotide excision repair-dependent monoubiquitylation of histone H2A. Genes Dev 2006, 20:1343-1352.
81. Pan M.R., Peng G., Hung W.C., Lin S.Y. Monoubiquitination of H2AX protein regulates DNA damage response signaling. J Biol Chem 2011, 286:28599-28607.
82. Wu C.Y., Kang H.Y., Yang W.L., et al. Critical role of monoubiquitination of histone H2AX protein in histone H2AX phosphorylation and DNA damage response. J Biol Chem 2011, 286:30806-30815.
83. Li W., Nagaraja S., Delcuve G.P., Hendzel M.J., Davie J.R. Effects of histone acetylation, ubiquitination and variants on nucleosome stability. Biochem J 1993, 296:737-744.
84. Chagraoui J., Hebert J., Girard S., Sauvageau G. An anticlastogenic function for the Polycomb Group gene Bmi1. Proc Natl Acad Sci U S A 2011, 108:5284-5289.
85. Campisi J., d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007, 8:729-740.
86. Grandinetti K.B., David G. Sin3B: an essential regulator of chromatin modifications at E2F target promoters during cell cycle withdrawal. Cell Cycle 2008, 7:1550-1554.
87. DiMauro T., Cantor D.J., Bainor A.J., David G. Transcriptional repression of Sin3B by Bmi-1 prevents cellular senescence and is relieved by oncogene activation. Oncogene 2015, 34:4011-4017.
88. Zhang F., Sui L., Xin T. Correlations of BMI-1 expression and telomerase activity in ovarian cancer tissues. Exp Oncol 2008, 30:70-74.
89. Greenberg R.A., O'Hagan R.C., Deng H., et al. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene 1999, 18:1219-1226.
90. Wu K.J., Grandori C., Amacker M., et al. Direct activation of TERT transcription by c-MYC. Nat Genet 1999, 21:220-224.
91. Chiba T., Seki A., Aoki R., et al. Bmi1 promotes hepatic stem cell expansion and tumorigenicity in both Ink4a/Arf-dependent and -independent manners in mice. Hepatology 2010, 52:1111-1123.
92. Hosen N., Yamane T., Muijtjens M., Pham K., Clarke M.F., Weissman I.L. Bmi-1-green fluorescent protein-knock-in mice reveal the dynamic regulation of bmi-1 expression in normal and leukemic hematopoietic cells. Stem Cells 2007, 25:1635-1644.
93. Lukacs R.U., Memarzadeh S., Wu H., Witte O.N. Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation. Cell Stem Cell 2010, 7:682-693.
94. Tian H., Biehs B., Warming S., et al. A reserve stem cell population in small intestine renders Lgr5-positive cells dispensable. Nature 2011, 478:255-259.
95. Zacharek S.J., Fillmore C.M., Lau A.N., et al. Lung stem cell self-renewal relies on BMI1-dependent control of expression at imprinted loci. Cell Stem Cell 2011, 9:272-281.
96. Ito K., Suda T. Metabolic requirements for the maintenance of self-renewing stem cells. Nat Rev Mol Cell Biol 2014, 15:243-256.
97. Conboy I.M., Rando T.A. Aging, stem cells and tissue regeneration: lessons from muscle. Cell Cycle 2005, 4:407-410.
98. Pekovic V., Hutchison C.J. Adult stem cell maintenance and tissue regeneration in the ageing context: the role for A-type lamins as intrinsic modulators of ageing in adult stem cells and their niches. J Anat 2008, 213:5-25.
99. Paranjape A.N., Balaji S.A., Mandal T., et al. Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog. BMC Cancer 2014, 14:785.
100. Zencak D., Lingbeek M., Kostic C., et al. Bmi1 loss produces an increase in astroglial cells and a decrease in neural stem cell population and proliferation. J Neurosci 2005, 25:5774-5783.
101. Iwama A., Oguro H., Negishi M., et al. Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. Immunity 2004, 21:843-851.
102. Oguro H., Yuan J., Ichikawa H., et al. Poised lineage specification in multipotential hematopoietic stem and progenitor cells by the polycomb protein Bmi1. Cell Stem Cell 2010, 6:279-286.
103. Bernstein B.E., Mikkelsen T.S., Xie X., et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006, 125:315-326.
104. Lowe S.W., Sherr C.J. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev 2003, 13:77-83.
105. Oguro H., Iwama A., Morita Y., Kamijo T., van Lohuizen M., Nakauchi H. Differential impact of Ink4a and Arf on hematopoietic stem cells and their bone marrow microenvironment in Bmi1-deficient mice. J Exp Med 2006, 203:2247-2253.
106. Bruggeman S.W., Valk-Lingbeek M.E., van der Stoop P.P., et al. Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. Genes Dev 2005, 19:1438-1443.
107. Fasano C.A., Dimos J.T., Ivanova N.B., Lowry N., Lemischka I.R., Temple S. shRNA knockdown of Bmi-1 reveals a critical role for p21-Rb pathway in NSC self-renewal during development. Cell Stem Cell 2007, 1:87-99.
108. Janzen V., Forkert R., Fleming H.E., et al. Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature 2006, 443:421-426.
109. Molofsky A.V., Slutsky S.G., Joseph N.M., et al. Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. Nature 2006, 443:448-452.
110. Chen K., Huang Y.H., Chen J.L. Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin 2013, 34:732-740.
111. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
112. Szotek P.P., Pieretti-Vanmarcke R., Masiakos P.T., et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A 2006, 103:11154-11159.
113. Haupt Y., Alexander W.S., Barri G., Klinken S.P., Adams J.M. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell 1991, 65:753-763.
114. Jacobs J.J., Scheijen B., Voncken J.W., Kieboom K., Berns A., van Lohuizen M. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev 1999, 13:2678-2690.
115. Glinsky G.V., Berezovska O., Glinskii A.B. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005, 115:1503-1521.
116. Cui H., Hu B., Li T., et al. Bmi-1 is essential for the tumorigenicity of neuroblastoma cells. Am J Pathol 2007, 170:1370-1378.
117. Leung C., Lingbeek M., Shakhova O., et al. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature 2004, 428:337-341.
118. Hemmati H.D., Nakano I., Lazareff J.A., et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A 2003, 100:15178-15183.
119. Hayry V., Tynninen O., Haapasalo H.K., et al. Stem cell protein BMI-1 is an independent marker for poor prognosis in oligodendroglial tumours. Neuropathol Appl Neurobiol 2008, 34:555-563.
120. Abdouh M., Facchino S., Chatoo W., Balasingam V., Ferreira J., Bernier G. BMI1 sustains human glioblastoma multiforme stem cell renewal. J Neurosci 2009, 29:8884-8896.
121. Godlewski J., Nowicki M.O., Bronisz A., et al. Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res 2008, 68:9125-9130.
122. Wang X., Venugopal C., Manoranjan B., et al. Sonic hedgehog regulates Bmi1 in human medulloblastoma brain tumor-initiating cells. Oncogene 2012, 31:187-199.
123. Bhattacharya R., Kwon J., Ali B., et al. Role of hedgehog signaling in ovarian cancer. Clin Cancer Res 2008, 14:7659-7666.
124. van Leenders G.J., Dukers D., Hessels D., et al. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol 2007, 52:455-463.
125. Song L.B., Zeng M.S., Liao W.T., et al. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 2006, 66:6225-6232.
126. Song L.B., Li J., Liao W.T., et al. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest 2009, 119:3626-3636.
127. Chou C.H., Yang N.K., Liu T.Y., et al. Chromosome instability modulated by BMI1-AURKA signaling drives progression in head and neck cancer. Cancer Res 2013, 73:953-966.
128. Yang M.H., Hsu D.S., Wang H.W., et al. Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat Cell Biol 2010, 12:982-992.
129. Prince M.E., Sivanandan R., Kaczorowski A., et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007, 104:973-978.
130. Guo B.H., Feng Y., Zhang R., et al. Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer. Mol Cancer 2011, 10:10.
131. Hoenerhoff M.J., Chu I., Barkan D., et al. BMI1 cooperates with H-RAS to induce an aggressive breast cancer phenotype with brain metastases. Oncogene 2009, 28:3022-3032.
132. Kreso A., van Galen P., Pedley N.M., et al. Self-renewal as a therapeutic target in human colorectal cancer. Nat Med 2014, 20:29-36.
133. Wang H., Pan K., Zhang H.K., et al. Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol 2008, 134:535-541.
134. Maynard M.A., Ferretti R., Hilgendorf K.I., Perret C., Whyte P., Lees J.A. Bmi1 is required for tumorigenesis in a mouse model of intestinal cancer. Oncogene 2014, 33:3742-3747.
135. Sawa M., Yamamoto K., Yokozawa T., et al. BMI-1 is highly expressed in M0-subtype acute myeloid leukemia. Int J Hematol 2005, 82:42-47.
136. Rizo A., Olthof S., Han L., Vellenga E., de Haan G., Schuringa J.J. Repression of BMI1 in normal and leukemic human CD34(+) cells impairs self-renewal and induces apoptosis. Blood 2009, 114:1498-1505.
137. Yuan J., Takeuchi M., Negishi M., Oguro H., Ichikawa H., Iwama A. Bmi1 is essential for leukemic reprogramming of myeloid progenitor cells. Leukemia 2011, 25:1335-1343.
138. Dovey J.S., Zacharek S.J., Kim C.F., Lees J.A. Bmi1 is critical for lung tumorigenesis and bronchioalveolar stem cell expansion. Proc Natl Acad Sci U S A 2008, 105:11857-11862.
139. Kim C.F., Jackson E.L., Woolfenden A.E., et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005, 121:823-835.
140. Lee K., Adhikary G., Balasubramanian S., et al. Expression of Bmi-1 in epidermis enhances cell survival by altering cell cycle regulatory protein expression and inhibiting apoptosis. J Invest Dermatol 2008, 128:9-17.
141. Li Z., Wang Y., Yuan C., et al. Oncogenic roles of Bmi1 and its therapeutic inhibition by histone deacetylase inhibitor in tongue cancer. Lab Invest 2014, 94:1431-1445.
142. Jung J.W., Lee S., Seo M.S., et al. Histone deacetylase controls adult stem cell aging by balancing the expression of polycomb genes and jumonji domain containing 3. Cell Mol Life Sci 2010, 67:1165-1176.
143. Wu J., Hu D., Yang G., et al. Down-regulation of BMI-1 cooperates with artemisinin on growth inhibition of nasopharyngeal carcinoma cells. J Cell Biochem 2011, 112:1938-1948.
144. Chou D.M., Adamson B., Dephoure N.E., et al. A chromatin localization screen reveals poly (ADP ribose)-regulated recruitment of the repressive polycomb and NuRD complexes to sites of DNA damage. Proc Natl Acad Sci U S A 2010, 107:18475-18480.
145. Levine S.S., Weiss A., Erdjument-Bromage H., Shao Z., Tempst P., Kingston R.E. The core of the polycomb repressive complex is compositionally and functionally conserved in flies and humans. Mol Cell Biol 2002, 22:6070-6078.
146. Boccuni P., MacGrogan D., Scandura J.M., Nimer S.D. The human L(3)MBT polycomb group protein is a transcriptional repressor and interacts physically and functionally with TEL (ETV6). J Biol Chem 2003, 278:15412-15420.
147. Margueron R., Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature 2011, 469:343-349.
148. Denisenko O., Shnyreva M., Suzuki H., Bomsztyk K. Point mutations in the WD40 domain of Eed block its interaction with Ezh2. Mol Cell Biol 1998, 18:5634-5642.
149. Cao R., Zhang Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol Cell 2004, 15:57-67.
150. Wilkinson F.H., Park K., Atchison M.L. Polycomb recruitment to DNA in vivo by the YY1 REPO domain. Proc Natl Acad Sci U S A 2006, 103:19296-19301.
151. Kirmizis A., Bartley S.M., Kuzmichev A., et al. Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev 2004, 18:1592-1605.
152. Haupt Y., Bath M.L., Harris A.W., Adams J.M. bmi-1 transgene induces lymphomas and collaborates with myc in tumorigenesis. Oncogene 1993, 8:3161-3164.
153. Proctor E., Waghray M., Lee C.J., et al. Bmi1 enhances tumorigenicity and cancer stem cell function in pancreatic adenocarcinoma. PloS One 2013, 8:e55820.